Alnylam Pharmaceuticals gains FDA approval for Amvuttra in ATTR-CM, boosting revenue prospects. Click here to read an ...

Fintel reports that on March 31, 2025, Redburn Atlantic initiated coverage of Alnylam Pharmaceuticals (NasdaqGS:ALNY) with a ...

Alnylam Pharmaceuticals (NasdaqGS:ALNY) saw a 13% share price increase in the last quarter, propelled by the FDA approval of Qfitlia™ for hemophilia A or B, a significant milestone reflecting its ...

Alnylam Pharmaceuticals (NasdaqGS:ALNY) saw a 17% price increase over the past week, likely influenced by its recent announcements and market trends. The company's R&D progress showcase on February 25 ...

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the Needham 24th Annual Virtual Healthcare ...

FDA approved Alnylam's Amvuttra for ATTR-CM, making it the first treatment cleared for both ATTR-CM and hATTR-PN in adults. In trials, Amvuttra cut mortality risk by 36% through 42 months and ...

Alnylam Pharmaceuticals, Inc. operates as biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics. It is the translation of RNAi as a new ...

Qfitlia Becomes the Sixth Alnylam-Discovered RNAi Therapeutic Approved by U.S. FDA and First and Only to Treat Hemophilia A or B With or Without Inhibitors – Alnylam Pharmaceuticals, Inc ...

Also, Alnylam wins an important approval for ATTR-CM. The FDA has approved Alynylam’s RNAi therapy Amvuttra for treating transthyretin amyloid cardiomyopathy (ATTR-CM), positioning it to ...

The Food and Drug Administration cleared Alnylam Pharmaceuticals’ treatment for a progressive heart condition Thursday, setting it up to compete with therapies from BridgeBio and Pfizer.